Remember the 2024 Henssler review claiming only 1 in 6 have antidepressant withdrawal symptoms & 1 in 30 severe symptoms? Here we show it was based on highly unreliable data & can't be used to assess withdrawal effects @ploederl.bsky.social @markhoro.bsky.social 1/n www.cambridge.org/core/journal...

To err is human. To leave out that you take money from 20 drug companies, were part of the original panel aimed to downplay withdrawal effects, to call for guidelines to be updated based on 10 week studies well that is divine. I think that's how the saying goes.

1. Are there robust subdistributions in antidepressant response? Should we dismiss the average efficacy as best estimation of efficacy? Our new paper is out (uncorrected proofs yet) where we tried to replicate the previously found trimodal subdistributions using data from the STAR*D trial.

"Low levels of serotonin, a key feature of depression,..." If you want to take action against the Kennedy BS, you should not BS yourself. @joannamoncrieff.bsky.social @markhoro.bsky.social @padbergthorsten.bsky.social @christophlane.bsky.social @mad-in-america.bsky.social

Wide-ranging discussion with Dr Alex Curmi psychiatrist and podcaster in the UK about withdrawal, “biological depression” and what drugs can and can’t do: bit.ly/3ZS642W bit.ly/3ZQVBol

Our MOST-VIEWED #Deprescribing webinar ever 👇🏽 Antidepressant withdrawal effects & how to safely 🛑 them ti.ubc.ca/antidepressa... ✅ Maudsley approach to deprescribe #antidepressants ✅ Hyperbolic tapering ✅ Distinguishing withdrawal effects Speaker: @markhoro.bsky.social #medsky #pharmsky

Useful blog from the National Clinical Director for Prescribing at NHS England about antidepressant deprescribing flagging overprescription, the need for services and the helpfulness of the Maudsley Deprescribing Guidelines bit.ly/41syj9t

Powerful account from @JoeTudor_ of how understanding his depression was caused by what was happening in his life and not the chemicals in his head gave him hope and the opportunity to move forward

It’s a pity that Prof Kendrick is advocating for more money to be spent on his CBT phoneline for patients stopping antidepressants when his trial showed that did not help people to stop the drugs. Money better spent on a helpline for tapering problems bit.ly/4ihUBk9

The most important findings of the REDUCE trial by Prof Kendrick was that about 60% patients who did not need to be on antidepressants were unable to stop with current approaches to tapering. 2 patients required urgent care Outlined here: bit.ly/3Zq8cym

We just published a short editorial Hidden Costs: The Clinical and Research Pitfalls of Mistaking Antidepressant Withdrawal for Relapse bit.ly/3Zq8cym with @drjamesdaviesbskys.bsky.social

Great to see!

Still no correction published for this meta-analysis about cariprazine for major depression. SE conflated with SD. Only 4 studies, the outlier is obvious, even more so as the original study findings were p>.05 but the CI in the forest plot clearly doesn't cover the null pubpeer.com/publications...